Necchi, A., Jong, J. D., Proudfoot, J. A., Maiorano, B. A., Cigliola, A., Tateo, V., Mercinelli, C., Ravasi, M., Davicioni, E., Moschini, M., Brembilla, G., Colecchia, M., Cobelli, F. D., Briganti, A., Montorsi, F. (2025). First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4518